Anti-Mouse PD-1 Monoclonal Antibodies

Background

The rat anti-mouse PD-1 monoclonal antibody (clone No. RMP1-14, rat IgG2a kappa) reacts with the mouse PD-1 protein (CD279 or programmed death-1) encoded by the mouse pdcd1 gene, a member of the CD28 family of the Ig superfamily. PD-1 has two ligands, PD-L1 and PD-L2, both of which belong to the B7 family. It has been shown that in mouse models of melanoma, tumor growth can be transiently arrested via treatment with the anti-mouse PD 1 antibody and the anti-mouse PD L1 antibody which block the interaction between the PD-L1 protein and its receptor PD-1 protein. The RMP1-14 antibody blocks the binding of both the mouse PD-L1 protein and the mouse PD-L2 protein to the mouse PD-1 protein.

Our recombinant RMP1-14 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse PD-1 antibody (hybridoma clone name or number: RMP1-14). The murinized anti-mouse PD-1 recombinant antibody has not only the constant regions of the mouse IgG antibodies but also the murinized variable regions.

PA007162.r2a: In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Rat IgG2a Kappa

The in vivo grade recombinant rat anti-mouse PD-1 monoclonal antibody (rat IgG2a kappa) was produced in mammalian cells. Its affinity to the mouse PD-1 protein is <2 nM.
Immunogen: The original rat hybridoma (clone name: RMP1-14) was generated by immunizing Sprague Dawley rats with mouse PD-1-transfected BHK cells and using a P3U1 myeloma as the fusion partner.
Clone: RMP1-14.1, the same variable region and constant region sequences as the rat anti-mouse PD-1 monoclonal antibody (clone number: RMP1-14).
Isotype: rat IgG2a, kappa.
Source: The anti-mouse PD-1 monoclonal antibody (clone: RMP1-14.1) was produced in mammalian cells.
Applications: immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.
RRID: AB_3697971

PA007162.m2cLA: In Vivo Grade Recombinant Anti-mouse PD-1 Monoclonal Antibody (Clone RMP1-14.1), Mouse IgG2c-L234A L235A P329G (LALAPG) Kappa

The in vivo grade recombinant rat anti-mouse PD-1 monoclonal antibody (mouse IgG2c-LALAPG kappa) was produced in mammalian cells. Its affinity to the mouse PD-1 protein is <2 nM.
Immunogen: The original rat hybridoma (clone name: RMP1-14) was generated by immunizing rats with mouse PD-1-transfected BHK cells.
Clone: RMP1-14.1, the same variable region sequences as the rat anti-mouse PD-1 monoclonal antibody (clone number: RMP1-14).
Isotype: mouse IgG2c, kappa.
Source: The anti-mouse PD-1 monoclonal antibody (clone: RMP1-14.1) was produced in mammalian cells.
Applications: immunohistochemistry (IHC), Flow Cytometry (FC), and various in vitro and in vivo functional assays.
Formulation: 0.2 μM filtered solution of 1x PBS.
Purity: >95% by SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU/mg of protein as determined by LAL method.

Shipping: The in vivo grade recombinant rat anti-mouse PD-1 monoclonal antibodies are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
1 month from date of receipt, 2 to 8°C as supplied.
12 months from date of receipt, -20°C to -70°C as supplied.

References of anti-mouse PD-1 antibody (RMP1-14)

Cooperative effects of programmed cell death-1 blockade and radiation in a model of a poorly immunogenic breast carcinoma.
Pilones, K. A., et al. Cancer Res. 74(19 Suppl):5020. doi: 10.1158/1538-7445.AM2014-5020. No PMID.
We have previously shown that radiation therapy (RT) converts poorly immunogenic tumors resistant to antibodies (mAbs) against the checkpoint receptor CTLA-4 into susceptible ones. Importantly, RT induced the upregulation of PDL-1 and PDL-2 on the tumor cells and infiltrating myeloid cells in the TSA mouse breast cancer, suggesting that PD-1 ligands may limit rejection of the irradiated tumor by T cells. PD-1 blocking mAb RMP1-14 (anti-mouse PD-1 antibody) was given on day 15 and every 4 days thereafter, and mice were followed for tumor growth. In contrast, when RT was combined with anti-PD-1 mAb (RMP1-14, anti-mouse PD-1 mAb), all of the mice completely rejected tumors by day 25. Overall, data suggest that the IgG2a anti-PD-1 mAb RMP1-14 (anti-mouse PD-1/CD279 antibody) selectively depletes CD8+PD-1hi TILs, possibly by ADCC, while enhancing the RT-elicited priming and activation of tumor-specific CD8+ T cells.
Tags: anti-mouse PD-1 mAb (RMP1-14); anti-mouse PD-1 for animal model

Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor.
Beavis, P. A., et al. Cancer Res. 74(14):3652-8. doi: 10.1158/0008-5472.CAN-14-0956. PMID: 24986517
Adenosine targeting is an attractive new approach to cancer treatment, but no clinical study has yet examined adenosine inhibition in oncology despite the safe clinical profile of adenosine A2A receptor inhibitors (A2ARi) in Parkinson disease. Metastasis is the main cause of cancer-related deaths worldwide, and therefore we have studied experimental and spontaneous mouse models of melanoma and breast cancer metastasis to demonstrate the efficacy and mechanism of a combination of A2ARi in combination with anti-PD-1 monoclonal antibody (mAb). This combination significantly reduces metastatic burden and prolongs the life of mice compared with either monotherapy alone. Importantly, the combination was only effective when the tumor expressed high levels of CD73, suggesting a tumor biomarker that at a minimum could be used to stratify patients that might receive this combination. Purified anti-mouse PD-1 mAb (RMP1-14, anti-mouse PD-1 antibody), anti-mouse CTLA-4 mAb (UC10-4F10), anti-mouse Tim3 (RMT3-23) and control Ig (2A3) were purchased from BioXCell (West Lebanon) and used in the schedule and dose as indicated.
Tags: activity of RMP1-14 antibody; RMP1-14 antibody mouse dose range

Selinexor synergizes with anti-PD-1 antibody and inhibits tumor growth and metastasis in syngeneic mouse models of KRAS mutant colorectal cancer.
Chang, H., et al. Cancer Res. 82(12_Suppl):5519. doi: 10.1158/1538-7445.AM2022-5519. No PMID.
Colorectal cancer (CRC) is the second leading cause of cancer related death. In approximately half of all CRC cases, oncogenic KRAS mutations underlie poor prognosis and drug resistance. We performed preclinical studies to evaluate the effectiveness of selinexor and the anti-PD-1 antibody RMP1-14 (anti-mouse PD-1 antibody) in syngeneic mouse models of KRAS mutant CRC. Mice were allocated to four groups: vehicle control, selinexor (15 mg/kg, PO, once weekly), RMP1-14 (300 µg/mouse, IP, once weekly), or the combination of selinexor and RMP1-14 (anti-mouse PD-1 mAb). The combination of selinexor and RMP1-14 (anti-mouse PD-1/CD279 antibody) significantly inhibited tumor growth and metastasis with a TGI of 98.9% (p<0.0001).
Tags: RMP1-14 mAb for cancer research; RMP1-14 mAb in vivo

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs.
Allard, B., et al. Clin Cancer Res. 19(20):5626-35. doi: 10.1158/1078-0432.CCR-13-0545. PMID: 23983257
Monoclonal antibodies (mAb) that block programmed death (PD)-1 or cytotoxic T lymphocyte antigen (CTLA-4) receptors have been associated with durable clinical responses against a variety of cancer types and hold great potential as novel cancer therapeutics. Recent evidence suggest that targeted blockade of multiple immunosuppressive pathways can induce synergistic antitumor responses. In this study, we investigated whether targeted blockade of CD73, an ectonucleotidase that catabolizes the hydrolysis of extracellular adenosine monophosphate (AMP) to adenosine, can enhance the antitumor activity of anti-CTLA-4 and anti-PD-1 mAbs against transplanted and chemically induced mouse tumors. Anti-CD73 mAb significantly enhanced the activity of both anti-CTLA-4 and anti-PD-1 mAbs against MC38-OVA (colon) and RM-1 (prostate) subcutaneous tumors, and established metastatic 4T1.2 breast cancer. Purified anti-mouse PD-1 mAb (clone RMP1-14, anti-mouse PD-1 antibody), purified anti-mouse CTLA-4 mAb (clone 9H10 and UC10-4F10), anti-mouse CD4 (clone GK1.5), anti-mouse CD8β (clone 53.5.8), and purified control Ig (MAC4) were purchased from...
Tags: RMP1-14 monoclonal antibody; RMP1-14 mAb for mouse tumor model

The Programmed Cell Death Ligand-1/Programmed Cell Death-1 Pathway Mediates Pregnancy-Induced Analgesia via Regulating Spinal Inflammatory Cytokines.
Zhang, X. J., et al. Anesth Analg. 133(5):1329-1339. doi: 10.1213/ANE.0000000000005730. PMID: 34524124
The maternal pain threshold gradually increases during pregnancy, especially in late pregnancy. A series of mechanisms underlying pregnancy-induced analgesia have been reported. However, these mechanisms are still not completely clear, and the underlying molecular mechanisms need further investigation. We examined the relationship between the antinociceptive effect and the expression level of programmed cell death ligand-1 (PD-L1) during pregnancy and further observed the changes in pain thresholds and expression levels of cytokines in late-pregnant mice before and after blockade of PD-L1 or programmed cell death-1 (PD-1). Part 2: Late-pregnant mice were assigned to 3 treatment groups (control [phosphate buffer solution], RMP1-14 [mouse anti–PD-1 antibody], and soluble PD-1 [sPD-1]).
Tags: RMP1-14 mAb in vivo; function of RMP1-14 antibody

For more references about anti-mouse PD-1 antibody (clone: RMP1-14), please contact our scientific support team with message@sydlabs.com.

Related Recombinant IgG Reference Antibodies:
In vivo Grade Recombinant Mouse IgG1 Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG2a Isotype Control Antibody and Mutants
In vivo Grade Recombinant Mouse IgG2c Isotype Control Antibody and Mutants
In vivo Grade Recombinant Rat IgG2a Isotype Control Antibody

Syd Labs provides the following anti-mouse PD-L1 / PD-1 antibodies:
In vivo grade recombinant anti-mouse PD1 antibodies (Clone 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-1 antibodies (Clone RMP1-14.1)
In vivo grade recombinant anti-mouse PD-L1 antibodies (Clone 10F.9G2.1)
In vivo grade recombinant anti-mouse PD-1 / PD-1 bispecific antibodies (Clone RMP1-14.1 / 29F.1A12.1)
In vivo grade recombinant anti-mouse PD-1 / PD-1 bispecific antibodies (Clone 29F.1A12.1 / RMP1-14.1)
In vivo grade recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies (Clone RMP1-14.1 / 10F.9G2.1)
In vivo grade recombinant anti-mouse PD-L1 / PD-1 bispecific antibodies (Clone 10F.9G2.1 / RMP1-14.1)
In vivo grade recombinant anti-mouse PD-1 / PD-L1 bispecific antibodies (Clone 29F.1A12.1 / 10F.9G2.1)
In vivo grade recombinant anti-mouse PD-L1 / PD-1 bispecific antibodies (Clone 10F.9G2.1 / 29F.1A12.1)

Recombinant PD1 and PDL1 Proteins:
Recombinant Human PD-1/PDCD1 Proteins
Biotinylated Recombinant Human PD-1/PDCD1 Proteins
Recombinant Mouse PD-1/PDCD1 Proteins
Biotinylated Recombinant Mouse PD-1/PDCD1 Proteins
Recombinant Cynomolgus PD-1/PDCD1 Proteins
Recombinant Canine PD-1/PDCD1 Proteins
Biotinylated Cynomolgus/Rhesus macaque PD-L1 Protein
Biotinylated Human PD-L1 Protein
Biotinylated Mouse PD-L1 Protein
Cynomolgus PD-L1 Protein
Cynomolgus/Rhesus macaque PD-L1 Protein
Human PD-L1/B7-H1 Protein
Mouse PD-L1/B7-H1 Protein

Questions and Answers about recombinant anti-mouse PD-1 antibody (Clone RMP1-14):

Question: Which anti-mouse PD1 antibody works the best?
Answer: (by AI) There are several anti-mouse PD1 antibodies available in the market: Clones RMP1-14, 29F.1A12, and J43. All three of these antibodies are commonly used to block PD-1 signaling in vivo in murine tumor models and other mouse models. These three clones all have extensive multi-year publication records supporting them. The RMP1-14 antibody has been reported to block the binding of PD-1 to its ligands (B7-H1 and B7-DC) and to inhibit T cell proliferation and cytokine production costimulated by macrophages (but not by dendritic cells and B cells). (by Syd Labs) Syd Labs offers anti-mouse PD-1 monoclonal antibodies based on the sequences of clones RMP1-14 and 29F.1A12. Syd Labs provides in vivo grade recombinant antibodies including engineered antibodies for the clones RMP1-14 and 29F.1A12. Even though mouse and rat are close, rat antibodies may still induce immunogenecity in mice. Antibodies with murinized variable regions and mouse constant regions behave like humanized antibody drugs in animal models using mice. In addition, the mouse IgG2c antibody is produced in certain inbred strains such as C57BL/6, C57BL/10, SJL, and NOD, which does not express the mouse IgG2a antibody; the mouse IgG2a antibody is produced in other inbred strains such as BALB/c and Swiss Webster mice, which does not express the mouse IgG2c antibody. If one uses the C57BL/6 mouse strain for animal model research, it is better to use the IgG2c antibodies rather than the IgG2a antibodies. The format with the Fc silenced, Fc silent, or Fcs with silenced effector function, such as LALAPG mutation, is the most popular for anti-mouse PD1 antibodies (clones RMP1-14 and 29F.1A12) and anti-mouse PD-L1 antibodies (clone 10F.9G2).

Question: Do you produce any recombinant Fc-silenced RMP1-14 antibody?
Answer: Sure, we provide various recombinant Fc silent RMP1-14 antibodies, such as mIgG2c LALAPG, mIgG2a LALAPG, and mIgG1 D265A. We also provide custom recombinant antibody production service to produce other engineered versions of recombinant RMP1-14 antibodies. We have a promotion program running: We provide 1 mg PA007162.m2cLA (In Vivo Grade Recombinant Anti-mouse PD-1 Mouse IgG2c-LALAPG Kappa Monoclonal Antibody (Clone RMP1-14.1)) for free in exchange of results. Please contact us to know more about the free RMP1-14 antibody.

Question: What is the difference among PA007162.r2a, PA007162.m2cLA, and PA007162.mm2cLA
Answer: PA007162.r2a is the recombinant anti-mouse PD-1 monoclonal antibody (rat IgG2a kappa, clone RMP1-14.1) produced in CHO cells or HEK293 cells if needed. It has the same variable region and constant region sequences as the rat anti-mouse PD-1 monoclonal antibody from the hybridoma clone of RMP1-14. Rat antibodies may cause high immuogenicity in mice; thus, at least recombinant antibodies with mouse antibody constant regions should be used to replace the rat antibody constant regions. PA007162.m2cLA is the recombinant anti-mouse PD-1 antibody (clone RMP1-14.1) whose constant regions are mouse IgG2c LALAPG kappa. We further murinize the antibody variable region sequences of PA007162.m2cLA to produce PA007162.mm2cLA.